Medicine and Dentistry
Adult T-Cell Leukemia/Lymphoma
100%
Overall Survival
72%
Multiple Myeloma
60%
Oncology
49%
Stem Cell Therapy
48%
Human T-Lymphotropic Virus 1
46%
Prevalence
43%
Esophageal Cancer
40%
Fulvestrant
40%
Cohort Effect
40%
Medicine
40%
Adenocarcinoma
40%
Central Nervous System
40%
Hormone Receptor
40%
Breast Cancer
40%
CAR T-cell therapy
40%
Combination Therapy
40%
Malignant Neoplasm
34%
Surveillance, Epidemiology, and End Results
34%
Human Immunodeficiency Virus
31%
Stem Cell
30%
COVID-19
30%
Hematologic Malignancy
30%
Stem Cell Transplant
30%
Patient Referral
27%
Diffuse Large B-Cell Lymphoma
25%
Infection
25%
Transplantation
24%
Clinical Trial
24%
Myelodysplastic Syndrome
24%
Acute Myeloid Leukemia
24%
Myelofibrosis
24%
Autologous Stem Cell Transplantation
22%
Biopsy
22%
Leukocyte
22%
Endoscopy
20%
Squamous Cell Carcinoma
20%
Seroconversion
20%
Gastroesophageal Reflux
20%
T Cell
20%
Desipramine
20%
Oligonucleotide
20%
Hepatic Veno-Occlusive Disease
20%
Hematopoietic Stem Cell
20%
Defibrotide
20%
Infectious Complication
20%
Matched Donor
20%
Lactate Dehydrogenase
20%
Antibiogram
20%
B-Cell Lymphoma
20%
Keyphrases
Adult T-cell Leukemia
60%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
45%
Lymphoma Patients
44%
Acute Myeloid Leukemia
40%
CAR T-cell Therapy
40%
Overall Survival
39%
Diffuse Large B-cell Lymphoma (DLBCL)
30%
Axicabtagene Ciloleucel
26%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
26%
United States
23%
Stem Cell Transplantation
23%
North America
22%
Caribbean
22%
Aromatase Inhibitor Therapy
21%
Progressive multifocal Leukoencephalopathy
20%
Albert Einstein
20%
American Adults
20%
Multi-ethnic
20%
Combination Therapy
20%
Myelodysplastic Syndrome
20%
Conventional Chemotherapy
20%
Clinical Potential
20%
Oligonucleotides
20%
Venetoclax
20%
Clinical Outcomes
20%
Mechanism of Action
20%
Epidemiological Trends
20%
Hepatic Veno-occlusive Disease
20%
Phosphodiester
20%
Esophageal Cancer
20%
Squamous Cell Carcinoma (SqCC)
20%
Defibrotide
20%
Stem Cells
20%
Polydisperse Mixtures
20%
Lifesaving
20%
SEER Analysis
20%
Viral Hepatitis
20%
Programmed Death-ligand 1 (PD-L1)
20%
Early Mortality
20%
Medical Center
20%
Non-cytotoxic
20%
Decitabine
20%
Hormone Receptor-positive Advanced Breast Cancer
20%
Intravenous Busulfan
20%
Targeted Oncology
20%
Janus Kinase 2 (JAK2)
20%
Large B-cell Lymphoma
20%
Endoscopic Ultrasound Imaging
20%
Clinical Entities
20%
Targeted Biopsy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
80%
Fulvestrant
60%
Hormone Receptor
60%
Overall Survival
48%
Myelodysplastic Syndrome
40%
Breast Cancer
40%
Combination Therapy
40%
T Cell Leukemia
40%
Clinical Trial
27%
Busulfan
22%
Phase II Trials
22%
Malignant Neoplasm
22%
Human T-Lymphotropic Virus 1
22%
Aromatase Inhibitor
21%
Gamma Urogastrone
20%
Acute Myeloid Leukemia
20%
Venetoclax
20%
Oligonucleotide
20%
Metastatic Breast Cancer
20%
Granulocyte Colony Stimulating Factor
20%
Liver Vein Obstruction
20%
Defibrotide
20%
Lenalidomide
20%
Melanoma
20%
Eltrombopag
20%
Everolimus
20%
Placebo
20%
Epidermal Growth Factor Receptor 2
20%
Enasidenib
20%
Bortezomib
20%
Decitabine
20%
Vaccination Policy
20%
HIV
20%
Melphalan
20%
Desipramine
20%
B Cell Lymphoma
20%
Protein Bcl 2
20%
Pharmacokinetics
20%
Myelofibrosis
20%
Neoplasm
18%
Oblimersen
16%
Progression Free Survival
16%
Disease
14%
Survival Rate
12%
Vein Occlusion
12%
Estrogen Receptor
10%
Myeloma
10%
SCID Mouse
10%
Anticoagulant Agent
8%
Oligodeoxyribonucleotide
7%